These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33252466)

  • 21. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis.
    Kaspar BK; Frost LM; Christian L; Umapathi P; Gage FH
    Ann Neurol; 2005 May; 57(5):649-55. PubMed ID: 15852403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.
    Payne C; Wiffen PJ; Martin S
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD008427. PubMed ID: 28387447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis.
    Majumder V; Gregory JM; Barria MA; Green A; Pal S
    BMC Neurol; 2018 Jun; 18(1):90. PubMed ID: 29954341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reply to: The Letter to be published with the Letter, Amyotrophic lateral sclerosis with frontotemporal dementia (ALS-FTD) syndrome as a phenotype of Creutzfeldt-Jakob disease (CJD)? A case report.
    Yaguchi H; Takeuchi A; Horiuchi K; Takahashi I; Shirai S; Akimoto S; Satoh K; Moriwaka F; Yabe I; Sasaki H
    J Neurol Sci; 2017 Apr; 375():490-491. PubMed ID: 28259353
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
    Mehta AR; Walters R; Waldron FM; Pal S; Selvaraj BT; Macleod MR; Hardingham GE; Chandran S; Gregory JM
    Brain Commun; 2019 Aug; 1(1):fcz009. PubMed ID: 32133457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis.
    Li L; Liu J; She H
    CNS Neurol Disord Drug Targets; 2019; 18(5):366-371. PubMed ID: 30963986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current clinical trials in amyotrophic lateral sclerosis.
    Bhatt JM; Gordon PH
    Expert Opin Investig Drugs; 2007 Aug; 16(8):1197-207. PubMed ID: 17685869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Untangling the knot: Lifetime physical exercise and amyotrophic lateral sclerosis.
    Chiò A; Mora G
    EBioMedicine; 2021 Jul; 69():103438. PubMed ID: 34157488
    [No Abstract]   [Full Text] [Related]  

  • 29. Sporadic Parkinson disease and amyotrophic lateral sclerosis complex (Brait-Fahn-Schwartz disease).
    Manno C; Lipari A; Bono V; Taiello AC; La Bella V
    J Neurol Sci; 2013 Mar; 326(1-2):104-6. PubMed ID: 23380453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Supportive care needs of patients with amyotrophic lateral sclerosis/motor neuron disease and their caregivers: A scoping review.
    Oh J; Kim JA
    J Clin Nurs; 2017 Dec; 26(23-24):4129-4152. PubMed ID: 28681543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular endothelial growth factor and amyotrophic lateral sclerosis: the interplay with exercise and noninvasive ventilation.
    Carilho R; de Carvalho M; Swash M; Pinto S; Pinto A; Costa J
    Muscle Nerve; 2014 Apr; 49(4):545-50. PubMed ID: 23868282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-based study of environmental/occupational lead exposure and amyotrophic lateral sclerosis: a systematic review and meta-analysis.
    Meng E; Mao Y; Yao Q; Han X; Li X; Zhang K; Jin W
    Neurol Sci; 2020 Jan; 41(1):35-40. PubMed ID: 31578652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis.
    Byrne S; Walsh C; Lynch C; Bede P; Elamin M; Kenna K; McLaughlin R; Hardiman O
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):623-7. PubMed ID: 21047878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease.
    Orrell RW; Lane JM; Ross MA
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002829. PubMed ID: 15495036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease.
    Orrell RW; Lane RJ; Ross M
    Cochrane Database Syst Rev; 2005 Jan; (1):CD002829. PubMed ID: 15674899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of the effect of moderate intensity exercise on function and disease progression in amyotrophic lateral sclerosis.
    Lui AJ; Byl NN
    J Neurol Phys Ther; 2009 Jun; 33(2):68-87. PubMed ID: 19556916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Communication vulnerable in patients with Amyotrophic Lateral Sclerosis: A systematic review.
    Neto LL; Constantini AC; Chun RYS
    NeuroRehabilitation; 2017; 40(4):561-568. PubMed ID: 28222570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyotrophic lateral sclerosis, occupational exposure to extremely low frequency magnetic fields and electric shocks: a systematic review and meta-analysis.
    Jalilian H; Najafi K; Khosravi Y; Röösli M
    Rev Environ Health; 2021 Mar; 36(1):129-142. PubMed ID: 32946420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis.
    Cykowski MD; Takei H; Schulz PE; Appel SH; Powell SZ
    Acta Neuropathol Commun; 2014 Dec; 2():171. PubMed ID: 25539830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Åstrand-Ryhming Test is not a Feasible Measure in Ambulatory Patients with Amyotrophic Lateral Sclerosis.
    van Groenestijn AC; Verschuren O; Schröder CD; van den Berg LH; Visser-Meily JM
    J Neuromuscul Dis; 2016 Nov; 3(4):539-544. PubMed ID: 27911333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.